本システムでは、JavaScriptを利用しています。JavaScriptを有効に設定してからご利用ください。
Skip to main content
Contact Us
Accessibility
LANGUAGE
JP
EN
HOME
About ASKA Pharmaceutical Holdings
Top Message
Corporate Philosophy
Company Overview
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Group Companies
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
IR News
IR Library
IR Calendar
Management Strategies and Policies
Governance
Financial Highlights
ASKA Pharmaceutical Holdings at a glance
IR Related Information
Stock and Shareholder Information
Sustainability
Our Sustainability
Environmental
Social
Governance (Related Link)
ESG Chart and ESG Data Book
External Evaluation
Initiatives and Member Organizations
Third-party Opinion
Sustainability News
Various Contrasting Tables
Policies (Related Link)
Integrated Report (Related Link)
Press Releases
Contact Us
Privacy Policy
Basic Policy on the Proper Handling of Specific Personal Information, etc.
Terms of Use
Web Accessibility Policy
SNS Community Guidelines
Official website and SNS
Sitemap
Search Results
Important Notice
About ASKA Pharmaceutical Holdings
Company Overview
Group Companies
Top Message
Corporate Philosophy
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
Management Strategies and Policies
IR News
IR Library
IR Calendar
Governance
Financial Highlights
ASKA Pharmaceutical Holdings at a glance
IR Related Information
Stock & Shareholder Information
Sustainability
Integrated Report (Related links)
Our Basic Policy for Sustainability
Various Contrasting Tables
Our Sustainability
Top Commitment
Our Basic Policy for Sustainability
Materiality
Value Creation Process
Capital and Strengths
Initiatives for Sustainability and SDGs
Importance of Female Healthcare and Social Issues
Disclosures based on TCFD recommendations
Disclosures based on TNFD recommendations
Environmental
Governance (Related links)
External Evaluation
Third-party Opinion
Various Contrasting Tables
Integrated Report (Related links)
Social
ESG Chart and ESG Data Book
Initiatives and Member Organizations
Sustainability News
Policies (Related links)
HOME
>
HOME
>
For Our Shareholders and Investors
>
Financial Highlights
>
Financial Statements
>
Consolidated Statements of Income
Consolidated Statements of Income
PRINT
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Cash Flows
[Based on Japanese GAAP]
Consolidated Statements of Income
(Unit: millions of yen)
Fiscal year ended
03/31/2025
Fiscal year ended
03/31/2026
Net sales
64,139
71,127
Cost of sales
32,803
36,982
Gross profit
31,335
34,145
Selling, general and administrative expenses
26,003
28,311
Operating profit
5,331
5,834
Non-operating income
Interest income
6
52
Dividend income
286
339
Rental income from real estate
38
157
Other
66
191
Total non-operating income
398
740
Non-operating expenses
Interest expenses
51
222
Share of loss of entities accounted for using equity method
53
293
Foreign exchange losses
123
161
Other
394
231
Total non-operating expenses
622
908
Ordinary profit
5,107
5,665
Extraordinary income
Subsidiary-related profit and loss
1,257
-
Gain on sale of investment securities
127
1,474
Other
-
96
Total extraordinary income
1,384
1,570
Extraordinary losses
Impairment losses
300
-
Loss on valuation of investment securities
-
244
Total extraordinary losses
300
244
Profit before income taxes
6,192
6,991
Income taxes - current
750
1,887
Income taxes - deferred
341
(521)
Total income taxes
1,091
1,366
Profit
5,101
5,625
Profit attributable to non-controlling interests
-
200
Profit attributable to owners of parent
5,101
5,424
(Unit: millions of yen)
Fiscal year ended
03/31/2025
Fiscal year ended
03/31/2026
(Consolidated statement of comprehensive income)
Profit
5,101
5,625
Other comprehensive income
Valuation difference on available-for-sale securities
60
787
Remeasurements of defined benefit plans, net of tax
(167)
665
Share of other comprehensive income of entities accounted for using equity method
228
(54)
Foreign currency translation adjustment
-
(448)
Total other comprehensive income
121
950
Comprehensive income
5,222
6,575
Comprehensive income attributable to
Owners of parent
5,222
6,590
Non-controlling interests
-
(14)
Consolidated Balance Sheets
Consolidated Statements of Cash Flows
About ASKA Pharmaceutical Holdings
Top Message
Corporate Philosophy
Company Overview
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Company Information
Organization Chart
Corporate History
Access Map
Policies
Video Library
Media Library
Group Companies
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
IR News
IR Library
IR Library
Financial Results and IR Events
Annual Securities Report
Integrated Report
Fact Sheet
Corporate Governance Report (Japanese version only, Related links)
Internal Control Report (Japanese version only, Related links)
Stock and Shareholder Information (Related links)
IR Calendar
Management Strategies and Policies
Management Strategies and Policies
Long-Term Vision ASKA VISION 2035
Medium-Term Management Plan
Pipeline and Intellectual Property
Business Risks
Disclosure Policy
IR Basic Policy
Disclaimer
Governance
Governance
Basic Principles / Corporate Governance Structure
Corporate Governance Basic Policy
Corporate Governance Report (Japanese version only)
Board Members
Compliance / Risk Management
Internal Control System
Internal Control Report (Japanese version only)
Dialogue with Shareholders
Message from Outside Directors
Financial Highlights
Financial Highlights
Performance Review
Performance Highlights
Financial Conditions
Financial Statements
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Cash Flows
Earnings Forecast
ASKA Pharmaceutical Holdings at a glance
ASKA Pharmaceutical Holdings at a glance
Point1 About ASKA - Understanding & History -
Point2 About ASKA - Our Strengths -
Point3 Highly Specialized Product Lineup
Point4 Continuously Evolving R&D
Point5 Stable Shareholder Returns
Frequently Asked Questions
Business Model
ASKA's Management Strategy
Medicine & Body Glossary
IR seminar for Individual Investors
IR Related Information
IR Related Information
IR E-mail Newsletter Service
IR Site Map
Recommended Route to Access Our IR Website
How to Use the IR Site
IR Inquiries
External Evaluation (IR)
Stock and Shareholder Information
Stock and Shareholder Information
Stock Summary Information
Shareholder Information
Shareholders' Meeting
Stock Price Information
Shareholder Return
Stock Procedures (Japanese version only)
Articles of Incorporation and Stock Handling Regulations
Analyst Coverage
Corporate Bonds and Ratings Information
Shareholder Newsletters (Japanese version only)
Privacy Policy (Shareholders)
Sustainability
Our Sustainability
Our Sustainability
Top Commitment
Our Basic Policy for Sustainability
Materiality
Value Creation Process
Capital and Strengths
Initiatives for Sustainability and SDGs
Importance of Female Healthcare and Social Issues
Disclosures based on TCFD recommendations
Disclosures based on TNFD recommendations
Environmental
Environmental
Environmental Management
Disclosures Based on TCFD Recommendations
Disclosures based on TNFD recommendations
Decarbonization Initiatives
Initiatives for Water Resource
Initiatives for Recycle-Oriented Society and Biodiversity
Social
Social
Stakeholder Engagement
Respect for Human Rights
Human capital/Labour Practices
Diversity & Inclusion
Initiatives to Promote the Advancement of Women
Health Management Initiatives
Ethics and Compliance
Supply Chain
Customer Health and Safety
Social Contribution Activities(Community Involvement and Development)
Multi-Stakeholder Policy
Governance (Related Link)
ESG Chart and ESG Data Book
External Evaluation
Initiatives and Member Organizations
Third-party Opinion
Sustainability News
Various Contrasting Tables
Policies (Related Link)
Integrated Report (Related Link)
Press Releases
Contact Us
Privacy Policy
Basic Policy on the Proper Handling of Specific Personal Information, etc.
Terms of Use
Web Accessibility Policy
SNS Community Guidelines
Official website and SNS
Sitemap
Search Results
Important Notice
TOP